SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of
Investors of The Medicines Company - MDCO
NEW YORK, Feb. 13, 2014
NEW YORK, Feb. 13, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims
on behalf of investors of The Medicines Company ("Medicines" or the
"Company")(NasdaqGS: MDCO). Such investors are advised to contact Robert S.
Willoughby at email@example.com or 888-476-6529, ext. 237.
The investigation concerns whether Medicines and certain of its officers
and/or directors have violated Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934.
On Monday, February 10, 2014, a report was published by the Food and Drug
Administration ("FDA") regarding Medicines drug candidate Cangrelor, designed
to prevent blood clots during heart artery-clearing angioplasty and stenting
procedures. The report found that Cangrelor did not show superiority to an
already approved drug, and that the clinical trials sponsored by Medicines
were unethically and inappropriately administered including by delaying
administration of the competing drug and lowering dosage of the competing
drug. The FDA report stated that, "because the CHAMPION trials were conducted
unethically. We can refuse approval of Cangrelor based on that fact alone."
On Thursday, February 13, 2014, Medicines announced that the FDA
Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to
recommend against approval of the intravenous antiplatelet agent Cangrelor for
use in patients undergoing percutaneous coronary intervention (PCI) -- or
cardiac stent procedures -- or those that require bridging from oral
antiplatelet therapy to surgery.
On this news, Medicines shares fell $4.45 per share to $28.65, or more than
13.44%, on February 13, 2014.
The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida,
is acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the Pomerantz Firm
pioneered the field of securities class actions. Today, more than 70 years
later, the Pomerantz Firm continues in the tradition he established, fighting
for the rights of the victims of securities fraud, breaches of fiduciary duty,
and corporate misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
SOURCE Pomerantz LLP
Press spacebar to pause and continue. Press esc to stop.